导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.93% | 1728/2676 |
| 近一周 | -1.17% | 941/3004 |
| 近一月 | -6.82% | 2320/2984 |
| 近一季 | 10.41% | 128/2896 |
| 近半年 | -1.79% | 1073/2746 |
| 近一年 | -15.19% | 2092/2519 |
| 近两年 | 18.44% | 1622/1796 |
| 近三年 | -9.41% | 1199/1340 |
| 成立以来 | -20.33% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.94% 2567/4961 |
-5.47% 3581/5312 |
- - |
- - |
| 2025 | 6.11% 2975/4813 |
1.65% 1577/3635 |
2.30% 1673/4076 |
15.97% 2745/4524 |
-12.01% 4229/4813 |
| 2024 | -12.10% 2364/3463 |
-10.38% 2337/2808 |
-8.19% 2184/3014 |
17.23% 1233/3129 |
-8.87% 2887/3463 |
| 2023 | -10.77% 1332/2656 |
1.42% 1574/2280 |
-8.20% 1971/2385 |
-2.12% 620/2515 |
-2.08% 421/2655 |
| 2022 | -19.36% 840/2207 |
-11.15% 483/1919 |
-1.77% 1751/2016 |
-15.57% 1316/2113 |
9.44% 222/2208 |
| 2021 | -5.80% 985/1822 |
-3.70% 822/1255 |
13.67% 279/1330 |
-12.92% 1323/1466 |
-1.18% 1326/1822 |
| 2020 | 48.85% 179/1250 |
7.30% 35/1028 |
28.56% 99/1067 |
3.30% 987/1164 |
4.45% 840/1184 |
| 2019 | 32.88% 439/1092 |
27.62% 340/754 |
-6.82% 525/804 |
6.53% 122/850 |
4.88% 770/918 |
| 2018 | -23.97% 310/834 |
- - |
- - |
- - |
-16.13% 624/691 |
| 2017 | 6.60% 333/714 |
- - |
- - |
- - |
- - |
| 2016 | -12.59% 306/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发医药卫生联接A VS. 长安沪深300非周期A(740101) |